Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reintroduction of Anti-TB Drugs After Hepatitis
NCT01395654Phase 4Unknown
- Sponsor
- National Taiwan University Hospital
- Start
- Jul 2011
- Primary completion
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of isoniazid, rifampicin and pyrazinamide in pulmonary tuberculosis (TB) (2 arms), sponsored by National Taiwan University Hospital. Primary endpoint: Duration needed for successfully rechallenge anti-tuberculosis treatment at 5 weeks. Status: unknown.
02
Drugs
isoniazidrifampicinpyrazinamide
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on NCT01395654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01395654.